Concomitant Weekly Cisplatin and Radiotherapy for Head and Neck Cancer

Homma, Akihiro; Inamura, Naoya; Suzuki, Seigo; Hatakeyama, Hyōe; Mizumachi, Takatsugu; Kano, Satoshi; Sakashita, Tetsuya; Onimaru, Rikiya; Yasuda, Kôichi; Shirato, Hiroki; Fukuda, Satoshi

doi:10.1093/jjco/hyr086

Cited by 79 publications

(68 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7,19] We reported the efficacy of weekly cis-platinum concurrent with RT; 3 years DFS, OS and LPS were 69%, 77% and 73% respectively. Our clinical results were consistent with other series; in spite of the smaller sample size with a shorter follow-up period.…”

Section: Discussionmentioning

confidence: 99%

“…More frequent chemotherapy administration could provide radiosensitizing effect to a larger administered RT dose proportion. [5][6][7] Concurrent CRT with weekly cisplatin has proven to be very effective and has been considered as the standard of care in the treatment of squamous carcinoma of the cervix. [15,16] Also, weekly cisplatin has been used successfully in concurrent CRT for bladder preservation.…”

Section: Discussionmentioning

confidence: 99%

“…[6] The feasibility of weekly cis-platinum is based on the evidence that a cumulative therapeutic chemotherapy dose (> 200 mg/m 2 ) considered to be essential for therapeutic benefit. [7] Aim of study To evaluate: 1) The larynx preservation, rates of disease control and overall survival. 2) Safety with weekly cis-platinum in our patients as regard of acute and late toxicity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Retrospective analysis of the clinical efficacy of concurrent weekly cisplatinum – radiotherapy for patients with laryngeal carcinoma

Aboziada

Elyamany

2016

JST

View full text Add to dashboard Cite

Introduction and aim: Laryngeal preservation with concurrent chemo-radiation is an effective, alternative management for cancer larynx. Three weekly cis-platinum concurrent with radiotherapy (RT) considered the standard. However, weekly cisplatinum has proven very effective for advanced head and neck carcinoma. We review our data to prove the efficacy and safety of weekly cis-platinum plus RT for laryngeal preservation. Patients and methods: Untreated 64 patients with advanced laryngeal carcinoma were retrospectively analyzed. Patients offered for 6 weeks of cis-platinum 40 mg/m 2 concurrent with conformal RT; 70 Gy delivered to gross primary and lymph nodes.Results: Forty-six (71.8%) patients had complete remission (CR). Early stages had better CR than late stages. Median follow up was 40 months. Three years DFS and OS were 69% and 77% respectively. Larynx preservation survival at 3 years was 73%. Protocol of treatment was tolerable, grade 3 or 4 acute and late toxic effects were reported in 25% of the included cases. Conclusion: Weekly cis-platinum could be effective and safe. We need to evaluate this protocol prospectively and compare it with three-weekly high dose cis-platinum with concomitant radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective analysis of the clinical efficacy of concurrent weekly cisplatinum – radiotherapy for patients with laryngeal carcinoma

Aboziada

Elyamany

2016

JST

View full text Add to dashboard Cite

show abstract

“…Systemic Toxicities (Hematological, Auditory, Renal Impairment) Most published reports have described the incidence of Grade 3 / 4 neutropenia as approximately 30% with 3-weekly cisplatin compared with 10 -15% with weekly cisplatin concurrent with RT, thus highlighting the importance of delivery of fractionated doses of chemotherapy (Cooper et al, 2004;Zenda et al, 2009;Homma et al, 2011;Mitra et al, 2011;Kiyota et al, 2012;Osman et al, 2014). Contradictory to this, various studies have reported no difference in terms of hematological toxicities between the two comparative arms (Kose et al, 2011;Tsan et al, 2012).…”

Section: 1617 Three Weekly Versus Weekly Cisplatin As Radiosensitizementioning

confidence: 99%

Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

Negi¹,

Kingsley²,

Srivastava³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cisplatin-based concurrent chemoradiation plays an undisputed key role as definitive treatment in unresectable patients with locally advanced squamous cell carcinoma head and neck or as an organ preservation strategy. Treatment with 100 mg/m2 3-weekly cisplatin is considered the standard of care but is often associated with several adverse events. The optimum drug schedule of administration remains to be defined and presently, there is insufficient data limiting conclusions about the relative tolerability of one regimen over the other. This review addresses regarding the optimal dose schedule of cisplatin focusing mainly on three-weekly and weekly dose of cisplatin based concurrent chemoradiotherapy in locally advanced head and neck cancer with an emphasis on mucositis, dermatitis, systemic toxicity, compliance, and treatment interruptions. To derive a definitive conclusion, large prospective randomized trials are needed directly comparing standard 3-weekly cisplatin (100 mg/m 2 ) with weekly schedule (30 -40 mg/m 2 ) of concurrent cisplatin based chemoradiotherapy in locally advanced squamous cell carcinoma head and neck.

show abstract

“…Single agent cisplatin given concurrently with radiation is the standard of care for squamous cell carcinomas of head and neck. 4,5 Newer agents like docetaxel and paclitaxel are most important because of their single agent activity in head and neck cancers and their ability to act as potent radio sensitizers. The purpose of this study is to explore the possibility of using weekly paclitaxel as an alternative to weekly cisplatin concurrent with conventional radiotherapy and to compare the response rate and toxicity of radical radiotherapy with weekly paclitaxel and cisplatin in head and neck cancers.…”

Section: Introductionmentioning

confidence: 99%

A comparative study of radical radiotherapy with weekly paclitaxel versus radical radiotherapy with weekly cisplatin in the management of locally advanced squamous cell carcinomas of head and neck

et al. 2017

View full text Add to dashboard Cite

Background: Concurrent chemo radiation is standard of care in locally advanced squamous cell carcinomas of head and neck. Single agent Cisplatin either weekly or three weekly is commonly used concurrently with radiation. The present study aims to evaluate the response rate and toxicity of radical radiotherapy with weekly paclitaxel and cisplatin in head and neck cancers.Methods: This is a prospective double arm study in which sixty patients with histologically proved squamous cell carcinomas registered in our department were accrued into the study with thirty patients in each arm. All patients were treated using Theratron phoenix 780 cobalt unit with a dose of 66 Gy in 33 fractions. The patients were randomized to receive 40 mg/m2 of weekly cisplatin or 40 mg/m2 of weekly Paclitaxel concurrently with radiation. The response to the therapy was assessed six weeks after completion of treatment. The statistical analysis was done using SPSS software.Results: In cisplatin group 18 patients achieved complete response and 12 patients achieved partial response whereas in Paclitaxel group 21 patients achieved complete response and 9 patients achieved partial response. However in paclitaxel arm the incidence of radiation dermatitis, mucositis, dysphagia and laryngitis are slightly higher compared to cisplatin group.Conclusions: The weekly paclitaxel concurrent with radiation is a feasible alternative to weekly cisplatin in locally advanced squamous cell carcinomas of head and neck.

show abstract

Concomitant Weekly Cisplatin and Radiotherapy for Head and Neck Cancer

Cited by 79 publications

References 19 publications

Retrospective analysis of the clinical efficacy of concurrent weekly cisplatinum – radiotherapy for patients with laryngeal carcinoma

Retrospective analysis of the clinical efficacy of concurrent weekly cisplatinum – radiotherapy for patients with laryngeal carcinoma

Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

A comparative study of radical radiotherapy with weekly paclitaxel versus radical radiotherapy with weekly cisplatin in the management of locally advanced squamous cell carcinomas of head and neck

Contact Info

Product

Resources

About